RANI Key Statistics, Chart & Performance
The current stock price of RANI is 1.35 USD. In the past month the price decreased by -10.6%. In the past year, price decreased by -10%.
RANI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RANI. When comparing the yearly performance of all stocks, RANI is a bad performer in the overall market: 83.36% of all stocks are doing better.
RANI Financial Highlights
Over the last trailing twelve months RANI reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 25.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -279.27% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RANI Forecast & Estimates
9 analysts have analysed RANI and the average price target is 9.44 USD. This implies a price increase of 598.89% is expected in the next year compared to the current price of 1.35.
RANI Ownership
About RANI
Company Profile
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Company Info
RANI THERAPEUTICS HOLDINGS-A
2051 Ringwood Avenue
San Jose CALIFORNIA US
CEO: Talat Imran
Employees: 105
Phone: 14084573700
RANI THERAPEUTICS HOLDINGS-A / RANI FAQ
Can you describe the business of RANI THERAPEUTICS HOLDINGS-A?
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
What is the stock price of RANI THERAPEUTICS HOLDINGS-A today?
The current stock price of RANI is 1.35 USD. The price decreased by -0.74% in the last trading session.
What is the dividend status of RANI THERAPEUTICS HOLDINGS-A?
RANI does not pay a dividend.
How is the ChartMill rating for RANI THERAPEUTICS HOLDINGS-A?
RANI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is RANI THERAPEUTICS HOLDINGS-A (RANI) stock traded?
RANI stock is listed on the Nasdaq exchange.
Can you provide the market cap for RANI THERAPEUTICS HOLDINGS-A?
RANI THERAPEUTICS HOLDINGS-A (RANI) has a market capitalization of 164.04M USD. This makes RANI a Micro Cap stock.
What is the outstanding short interest for RANI THERAPEUTICS HOLDINGS-A?
The outstanding short interest for RANI THERAPEUTICS HOLDINGS-A (RANI) is 15.13% of its float.